Benjamin Malcolm
Founder of Spirit Pharmacist; Psychopharmacology Consultant and Psychedelic Educator
Data updated
Research Footprint
Benjamin Malcolm appears in 5 tracked papers (2017–2022), most studied alongside Psilocybin, Ibogaine and MDMA, across Depressive Disorders, Anxiety Disorders and Medicinal Chemistry & Drug Development.
Most-cited paper: Serotonin toxicity of serotonergic psychedelics (131 citations).
Frequent co-authors: Joseph Barsuglia, Martin Polanco and Christopher Stauffer.
Background & Research
Benjamin Malcolm is a clinically trained psychiatric pharmacist with a BS in Pharmacology from UC Santa Barbara, and an MPH and PharmD from Touro University California. He completed PGY-1 training at Scripps Mercy Hospital and PGY-2 training in Psychiatric Pharmacy at UC San Diego Health, then worked in academia before founding Spirit Pharmacist. His work focuses on the intersection of psychiatric medications and psychedelic therapies, and he has published peer-reviewed articles on psychedelic drug interactions and safety.
Key Impact
He is a recognized expert on psychedelic pharmacology and drug interactions, with peer-reviewed work spanning psilocybin, MDMA, ketamine, ibogaine, and serotonin toxicity.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Benjamin Malcolm is associated with.
Spirit Pharmacist LLC
Psychedelic Medicine Association
nonprofitThe Psychedelic Medicine Association (PMA) is a professional association that educates and connects healthcare practitioners about the therapeutic use of psychedelic medicines. It also develops clinical practice guidelines, training accreditation, and related infrastructure to support safe integration of psychedelic therapies into mainstream healthcare.
View stakeholder →